Medigene broadens alliance on T-cell receptors with Bluebird Bio

Medigene AG

14/05/2018 07:58

FRANKFURT, May 14 (Reuters) - German biotech firm Medigene
has secured a wider remit under a collaboration with U.S. peer
Bluebird Bio  BLUE.O  on technology that boosts the immune
response to cancer, increasing the pool of potential milestone
payments to $1.5 billion.
    The number of projects in the alliance, which has Medigene
contributing screening tools to identify promising T-cell
receptors (TCR), will rise from four to six, Medigene said in a
statement on Monday. 
    "If successfully developed and marketed through several
indications and markets, Medigene could receive up to $250
million in milestone payments per TCR program in addition to
tiered royalty payments on net sales up to a double-digit
percentage," Medigene said.
    Medigene agreed its alliance with Bluebird in September
2016.   
    
    

 (Reporting by Ludwig Burger; editing by John Stonestreet)
 ((ludwig.burger@thomsonreuters.com; +49 69 7565 1311; Reuters
Messaging: ludwig.burger.thomsonreuters.com@reuters.net))